Key Highlights
- Tech giants linked to AI including Broadcom, AMD, Nvidia, and Super Micro rebounded Monday following Friday’s market decline
- Eli Lilly climbed as much as 5% following positive Foundayo obesity medication trial results demonstrating effectiveness across menopause stages
- Nurix Therapeutics skyrocketed 38% on announcement of $2.3B collaboration agreement with Roche featuring $700M immediate payment
- Marvell Technology and Flex advanced following confirmation of S&P 500 addition effective June 22
- Honeywell declined 2% despite confirming annual guidance and detailing organizational changes post-aerospace separation
Monday morning trading showed signs of recovery from Friday’s AI sector weakness. Technology shares advanced in early sessions as investors looked beyond geopolitical developments involving Israel and Iran alongside previous week’s tech sector pressures.
Broadcom climbed 1.5% before the opening bell following two consecutive down sessions linked to disappointing revenue projections. AMD advanced 1.6%, Nvidia rose 1.9%, and Super Micro Computer surged 7.7%. Additional semiconductor names including Micron Technology, Lam Research, Seagate, and Western Digital also prepared for higher openings.
Positive Trial Results Drive Eli Lilly Higher
Eli Lilly emerged as a top performer Monday, climbing between 3.9% and 5%. The pharmaceutical company disclosed updated findings from its ATTAIN-1 and ATTAIN-2 clinical studies during the weekend.
The studies demonstrated that Foundayo produced weight reduction outcomes in female participants independent of menopause status. Women receiving the maximum dosage in the ATTAIN-1 study experienced body weight decreases ranging from 12.8% to 14.4% throughout the 72-week period.
Approximately 83% of study participants achieved weight loss of at least 5%. A substantial 52% experienced weight reduction of 15% or greater. These outcomes were consistent across premenopausal, perimenopausal, and postmenopausal participant groups.
The clinical evidence strengthens the business outlook for Lilly’s obesity treatment portfolio and may facilitate upcoming insurance coverage negotiations with payers and healthcare systems.
Nurix Shares Soar Following Major Roche Partnership
Nurix Therapeutics emerged as Monday’s top individual stock performer, with shares climbing 38% following disclosure of a significant partnership with Roche.
The worldwide exclusive licensing and collaboration arrangement encompasses development and marketing of bexobrutinib, an oral BTK degrader compound. The agreement carries a maximum value of $2.3 billion.
Nurix will receive $700 million in immediate cash compensation. Roche will assume 60% of development expenses, while Nurix contributes the remaining 40%. The partners will split U.S. market profits and losses on equal terms.
For international markets, Roche assumes commercialization duties and compensates Nurix with tiered royalty payments ranging from low-to-high teen percentages. The agreement’s non-dilutive financing structure received positive investor response.
Both companies intend to initiate a Phase 3 clinical study during summer months targeting chronic lymphocytic leukemia. Additional therapeutic applications being investigated include multiple sclerosis and chronic spontaneous urticaria.
S&P 500 Additions and Honeywell Update
Marvell Technology and Flex both appreciated following S&P Dow Jones Indices’ confirmation of their June 22 addition to the S&P 500. Marvell surged 6.7% while Flex increased 3%.
Honeywell dropped 2% despite maintaining its 2026 annual sales forecast of $38.8 billion to $39.8 billion. The industrial conglomerate also unveiled a revised financial structure for its automation-centered division in preparation for the aerospace unit separation planned for June 29.
Apple inched up 0.3% in anticipation of its 2026 Worldwide Developer Conference, which commenced Monday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
